Apr 16 |
Turnstone Biologics Appoints William Waddill to its Board of Directors
|
Apr 5 |
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
|
Apr 3 |
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
|
Apr 1 |
Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%
|
Mar 26 |
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
|
Mar 18 |
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
|
Mar 18 |
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
|
Mar 11 |
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
|
Mar 9 |
Johnson & Johnson highlights psoriasis candidate with long-term data
|
Mar 5 |
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
|